Zimbabwe has rejected a substantial US health deal worth 367 million US dollars (£272m) spanning five years over the United States' demand for confidential data.
The decision came to light after a official document from December was leaked, indicating that President Emmerson Mnangagwa deemed the deal was "unbalanced".
An official spokesman has since stated that the United States was seeking genetic material for research and commercial gain but refused to share the benefits from any future medical innovations.
"We must now begin the difficult and regrettable process of winding down our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged further dialogue to reach a agreement agreeable to both sides so the country's vital HIV treatment initiative can be sustained.
Wider Implications
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a court halted a related health funding agreement following legal challenges were filed about the security of citizens' health data.
Since returning to office recently, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump stated its spending was "inefficient" and his government was seeking government-to-government deals to boost transparency and accountability.
As per statements, Sixteen African countries have to date agreed to similar agreements, constituting more than $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment through American-funded initiatives," Tremont commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, without any corresponding guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"In essence, our country would provide the raw materials for medical research with no assurance that the end products would be available to our population if a future health crisis arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the global health body and its pursuit of one-on-one deals were disrupting frameworks already set up through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme designed to manage potential global health emergencies.
"This system is designed to ensure that when a country provides its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to develop them."
The government's concerns regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We encourage continued dialogue with our US partners on how subsequent co-operation could be designed in a way that honours the sovereignty and interests of both nations."
Health Experts Response
A leading public health body stated it understood the official position, but suggested that talks should continue given that much of the country's Aids initiatives relied on external financing.
"Where specific concerns exist, including those involving information security or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," it said.
This impasse highlights the ongoing challenges between accepting crucial foreign assistance and protecting local interests in an increasingly data-driven world.